Recent News

Eli Lilly Partnership Continues in Medical Affairs Oncology

Eli Lilly continues to partner with The Chase Group to build the Medical Affairs Oncology team for their Cyramza® portfolio. The Chase Group is currently… Continue Reading →

Genmab Selects The Chase Group to Build Data Science Team

Genmab A/S specializes in the creation and development of antibody therapeutics for the treatment of cancer. When highly specialized talent is needed, Genmab relies on… Continue Reading →

Oncology Teams Set to Grow with Eli Lilly and The Chase Group Partnership

Lilly Oncology is known for its exciting pipeline across multiple tumor types and dedication to addressing the unmet needs of people living with cancer. Their… Continue Reading →

Aeglea BioTherapeutics (NASDAQ: AGLE) Partners with The Chase Group to Build Clinical Development Team for Rapidly Expanding Genetic Rare Disease Portfolio

As a leader in engineering human enzymes to address significant unmet medical needs in rare genetic diseases and cancer, Aeglea BioTherapeutics is committed to using… Continue Reading →

International Next-Generation Immunotherapy Developer Partners with The Chase Group to Build New Executive Team

The Chase Group is pleased to announce our recent partnership and executive search engagement with the international biopharmaceutical company, Immunovative Therapies, Ltd. (ITL), currently headquartered… Continue Reading →